Strata Critical Medical shares rise 11.74% premarket after Q3 revenue jumps 36.7% to $49.3M and EBITDA surges 93.5%.

Strata Critical Medical surged 11.74% in premarket trading following the release of its Q3 2025 results, which highlighted a 36.7% year-over-year revenue increase to $49.3 million, driven by strong performance in Air and Ground Logistics and a doubling of Organ Placement Services revenue. The company also announced the successful integration of its recently acquired Keystone Perfusion division, which bolstered its position as an end-to-end organ recovery platform. Management emphasized a 93.5% year-over-year rise in Medical Segment Adjusted EBITDA to $7.6 million and raised 2025 revenue guidance to $185–195 million. Additionally, Strata rebranded to focus exclusively on healthcare services and outlined strategic growth opportunities in NRP adoption and expanded logistics capabilities, reinforcing investor confidence in its long-term value creation.